The Role of Structural and Functional Imaging in Parkinsonian States with a Description of PET Technology

David J. Brooks

doi:10.1055/s-0028-1083690

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2008; 28(4): 435-445
DOI: 10.1055/s-0028-1083690

The Role of Structural and Functional Imaging in Parkinsonian States with a Description of PET Technology

David J. Brooks¹

¹Division of Neuroscience and Medical Research Council Clinical Sciences Centre, Imperial College, London, United Kingdom

Abstract

ABSTRACT

In this article, after providing a description of the technique of brain positron emission tomography (PET), the review focuses on the application of PET and other recent advances of neuroimaging in understanding the structural, pathophysiological, and pharmacological changes associated with Parkinson's disease (PD). In early cases of PD, demonstration of the presence of nigral structural abnormalities with transcranial sonography and striatal dopaminergic dysfunction with functional imaging provides a rationale for the use of dopaminergic medications. The presence of altered striatal signal with diffusion-weighted magnetic resonance imaging (DWI) or reduced lentiform nucleus glucose metabolism with fluorodeoxyglucose PET suggests the presence of an atypical PD variant. Finally, the value of functional imaging as a biomarker for following the progression of PD and for understanding mechanisms of dementia when present is debated.

KEYWORDS

PET - SPECT - MRI - Parkinson - dementia

Volltext

Referenzen

REFERENCES

1 Fearnley J M, Lees A J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991; 114 2283-2301
2 Gasser T. Update on the genetics of Parkinson's disease. Mov Disord. 2007; 22 (suppl 17) S343-S350
3 Siderowf A, Stern M B. Preclinical diagnosis of Parkinson's disease: are we there yet?. Curr Neurol Neurosci Rep. 2006; 6 295-301
4 Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol. 2001; 248 684-689
5 Brooks D J. Neuroimaging in Parkinson's disease. NeuroRx. 2004; 1 243-254
6 Laruelle M, Baldwin R M, Malison R T et al.. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993; 13 295-309
7 Eidelberg D, Moeller J R, Dhawan V et al.. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab. 1994; 14 783-801
8 Feigin A, Fukuda M, Dhawan V et al.. Metabolic correlates of levodopa response in Parkinson's disease. Neurology. 2001; 57 2083-2088
9 Eckert T, Barnes A, Dhawan V et al.. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005; 26 912-921
10 Hutchinson M, Raff U. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. AJNR Am J Neuroradiol. 2000; 21 697-701
11 Hu M T, White S J, Herlihy A H et al.. A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology. 2001; 56 1195-1200
12 Minati L, Grisoli M, Carella F et al.. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. AJNR Am J Neuroradiol. 2007; 28 309-313
13 Michaeli S, Oz G, Sorce D J et al.. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord. 2007; 22 334-340
14 Geng D Y, Li Y X, Zee C S. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease. Neurosurgery. 2006; 58 256-262
15 Savoiardo M. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci. 2003; 24(suppl 1) S35-S37
16 Schrag A, Good C D, Miszkiel K et al.. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology. 2000; 54 697-702
17 Schocke M F, Seppi K, Esterhammer R et al.. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology. 2002; 58 575-580
18 Seppi K, Schocke M F, Esterhammer R et al.. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology. 2003; 60 922-927
19 Nicoletti G, Lodi R, Condino F et al.. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain. 2006; 129(Pt 10) 2679-2687
20 Paviour D C, Thornton J S, Lees A J, Jager H R. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov Disord. 2007; 22 68-74
21 Stockner H, Sojer M et al.. Midbrain sonography in patients with essential tremor. Mov Disord. 2007; 22 414-417
22 Walter U, Hoeppner J, Prudente-Morrissey L et al.. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain. 2007; 130(Pt 7) 1799-1807
23 Prestel J, Schweitzer K J, Hofer A, Gasser T, Berg D. Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. Mov Disord. 2006; 21 1763-1765
24 Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord. 2005; 20 383-385
25 Berg D, Roggendorf W, Schroder U et al.. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol. 2002; 59 999-1005
26 Walter U, Dressler D, Probst T et al.. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol. 2007; 64 1635-1640
27 Morrish P K, Sawle G V, Brooks D J. Clinical and [18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 1995; 59 597-600
28 Marek K L, Seibyl J P, Zoghbi S S et al.. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996; 46 231-237
29 Benamer T S, Patterson J, Grosset D G et al.. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT imaging: The [123I]-FP-CIT Study Group. Mov Disord. 2000; 15 503-510
30 Jennings D L, Seibyl J P, Oakes D et al.. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol. 2004; 61 1224-1229
31 Catafau A M, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004; 19 1175-1182
32 Tolosa E, Borght T V, Moreno E. Accuracy of DaTSCAN ((123)I-ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007; 22 2346-2351
33 Hughes A J, Ben-Shlomo Y, Daniel S E, Lees A J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathological study. Neurology. 1992; 42 1142-1146
34 Fahn S, Oakes D, Shoulson I et al.. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004; 351 2498-2508
35 Parkinson Study Group . Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002; 287 1653-1661
36 Whone A L, Watts R L, Stoessl J et al.. Slower progression of PD with ropinirol versus L-dopa: the REAL-PET study. Ann Neurol. 2003; 54 93-101
37 Marshall V L, Patterson J, Hadley D M, Grosset K A, Grosset D G. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun. 2006; 27 933-937
38 Ahlskog J E. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2003; 60 381-389
39 Jenner P, Olanow C W. Understanding cell death in Parkinson's disease. Ann Neurol. 1998; 44 S72-S84
40 Schapira A H, Olanow C W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004; 291 358-364
41 Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2003; 2 229-237
42 Summerfield C, Junque C, Tolosa E et al.. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol. 2005; 62 281-285
43 Ramirez-Ruiz B, Marti M J, Tolosa E et al.. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J Neurol. 2005; 252 1345-1352
44 Burton E J, McKeith I G, Burn D J, O'Brien J T. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord. 2005; 20 1571-1576
45 Foster N L, Chase T N, Fedio P et al.. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology. 1983; 33 961-965
46 Peppard R F, Martin W RW, Carr G D et al.. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol. 1992; 49 1262-1268
47 Vander-Borght T, Minoshima S, Giordani B et al.. Cerebral metabolic differences in Parkinson's and Alzheimer's disease matched for dementia severity. J Nucl Med. 1997; 38 797-802
48 Yong S W, Yoon J K, An Y S, Lee P H. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol. 2007; 14 1357-1362
49 Hu M TM, Taylor-Robinson S D, Chaudhuri K R et al.. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18FDG)-PET study. Brain. 2000; 123 340-352
50 Walker Z, Costa D C, Walker R W et al.. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002; 73 134-140
51 Walker Z, Jaros E, Walker R W et al.. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT SPECT imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007; 78 1176-1181
52 O'Brien J T, Colloby S, Fenwick J et al.. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol. 2004; 61 919-925
53 Ito K, Nagano-Saito A, Kato T et al.. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain. 2002; 125(Pt 6) 1358-1365
54 Kuhl D E, Minoshima S, Fessler J A et al.. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol. 1996; 40 399-410
55 Hilker R, Thomas A V, Klein J C et al.. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005; 65 1716-1722
56 Bohnen N I, Kaufer D I, Hendrickson R et al.. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol. 2006; 253 242-247
57 Bacskai B J, Frosch M P, Freeman S H et al.. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007; 64 431-434
58 Klunk W E, Engler H, Nordberg A et al.. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55 306-319
59 Edison P, Archer H A, Hinz R et al.. Amyloid, hypometabolism, and cognition in Alzheimer disease—an [11C]PIB and [18F]FDG PET study. Neurology. 2007; 68 501-508
60 Rowe C C, Ng S, Ackermann U et al.. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007; 68 1718-1725

David J BrooksM.D. D.Sc. F.R.C.P. F.Med.Sci.

Hartnett Professor of Neurology, Cyclotron Building, Hammersmith Hospital, Du Cane Road

London W12 0NN, United Kingdom

eMail: david.brooks@csc.mrc.ac.uk